Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BSX Stock Forecast 2026-2027
$68.55
Current Price
$101.72B
Market Cap
Buy 35
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BSX Price Targets
+80.9%
To High Target of $124.00
+53.2%
To Median Target of $105.00
+21.1%
To Low Target of $83.00
BSX Price Momentum
-3.9%
1 Week Change
-8.3%
1 Month Change
-28.1%
1 Year Change
-28.1%
Year-to-Date Change
-37.4%
From 52W High of $109.50
+1.5%
From 52W Low of $67.56
📊 TOP ANALYST CALLS
Did BSX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Boston Scientific is one of their latest high-conviction picks.
Latest BSX Stock Price Targets & Analyst Predictions
Based on our analysis of 33 Wall Street analysts, BSX has a bullish consensus with a median price target of $105.00 (ranging from $83.00 to $124.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $68.55, the median forecast implies a 53.2% upside. This outlook is supported by 35 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matt Miksic at Barclays, projecting a 80.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BSX Analyst Ratings
35
Buy
0
Hold
0
Sell
BSX Price Target Range
Low
$83.00
Average
$105.00
High
$124.00
Current: $68.55
Latest BSX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BSX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2026 | Citigroup | Joanne Wuensch | Buy | Maintains | $94.00 |
| Feb 17, 2026 | Canaccord Genuity | William Plovanic | Buy | Maintains | $109.00 |
| Feb 9, 2026 | BTIG | Marie Thibault | Buy | Reiterates | $110.00 |
| Feb 5, 2026 | Baird | David Rescott | Outperform | Maintains | $101.00 |
| Feb 5, 2026 | Citigroup | Joanne Wuensch | Buy | Maintains | $102.00 |
| Feb 5, 2026 | Canaccord Genuity | William Plovanic | Buy | Maintains | $112.00 |
| Feb 5, 2026 | RBC Capital | Shagun Singh | Outperform | Maintains | $115.00 |
| Feb 5, 2026 | Truist Securities | Richard Newitter | Buy | Maintains | $95.00 |
| Feb 5, 2026 | Needham | Mike Matson | Buy | Maintains | $97.00 |
| Feb 5, 2026 | JP Morgan | Robbie Marcus | Overweight | Maintains | $100.00 |
| Feb 5, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $96.00 |
| Feb 5, 2026 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $94.00 |
| Feb 5, 2026 | TD Cowen | Joshua Jennings | Buy | Maintains | $100.00 |
| Feb 5, 2026 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $118.00 |
| Feb 5, 2026 | Stifel | Rick Wise | Buy | Maintains | $110.00 |
| Feb 5, 2026 | UBS | Danielle Antalffy | Buy | Maintains | $120.00 |
| Feb 5, 2026 | Mizuho | Anthony Petrone | Outperform | Maintains | $115.00 |
| Feb 4, 2026 | BTIG | Marie Thibault | Buy | Maintains | $110.00 |
| Feb 3, 2026 | Barclays | Matt Miksic | Overweight | Maintains | $124.00 |
| Jan 16, 2026 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $100.00 |
Boston Scientific Corporation (BSX) Competitors
The following stocks are similar to Boston Scientific based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BSX
Boston Scientific
mkt cap
105.88B
Boston Scientific Corporation (BSX) Financial Data
Boston Scientific Corporation has a market capitalization of $101.72B with a P/E ratio of 35.3x. The company generates $20.07B in trailing twelve-month revenue with a 14.4% profit margin.
Revenue growth is +15.9% quarter-over-quarter, while maintaining an operating margin of +19.7% and return on equity of +12.4%.
Valuation Metrics
Market Cap
$101.72B
Enterprise Value
$111.97B
P/E Ratio
35.3x
PEG Ratio
1.9x
Price/Sales
5.1x
Growth & Margins
Revenue Growth (YoY)
+15.9%
Gross Margin
+69.6%
Operating Margin
+19.7%
Net Margin
+14.4%
EPS Growth
+18.9%
Financial Health
Cash/Price Ratio
+1.9%
Current Ratio
1.6x
Debt/Equity
48.9x
ROE
+12.4%
ROA
+6.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Boston Scientific Corporation (BSX) Business Model
About Boston Scientific Corporation
What They Do
Develops medical devices for interventional procedures.
Business Model
The company operates through two main segments: MedSurg and Cardiovascular, generating revenue by providing a range of innovative medical devices for various interventional procedures. Its offerings include devices for gastrointestinal conditions, cardiac rhythm management, and neuromodulation, catering to healthcare professionals and institutions globally.
Additional Information
Founded in 1979 and headquartered in Marlborough, Massachusetts, the company emphasizes minimally invasive therapies and has a significant portion of its sales derived from international markets. Boston Scientific is committed to advancing medical device innovation to enhance patient outcomes.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
59,000
CEO
Mr. Michael F. Mahoney
Country
United States
IPO Year
1992
Website
www.bostonscientific.comBoston Scientific Corporation (BSX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
Boston Scientific (BSX) closed the most recent trading day at $68.55, moving 1.55% from the previous trading session.
Mar 12, 2026
By Zacks Equity Research
Tale of the Tape
Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mar 06, 2026
By Zacks Equity Research
Realtime BLOG
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Mar 06, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Boston Scientific shareholders from July 23, 2025, to February 3, 2026, may contact Bernstein Liebhard for details on a shareholder lawsuit.
Why It Matters
The shareholder lawsuit could impact Boston Scientific's stock price and investor confidence, potentially leading to volatility and legal costs that affect financial performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors in Boston Scientific (NYSE: BSX) from July 23, 2025, to February 3, 2026, can apply to be lead plaintiff in a class action lawsuit by May 4, 2026.
Why It Matters
The announcement indicates potential legal risks for Boston Scientific, which could affect stock performance and investor sentiment during the lawsuit period.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Boston Scientific Corporation (NYSE: BSX). Investors can contact Pomerantz LLP for more information.
Why It Matters
A class action lawsuit against Boston Scientific may signal legal risks and potential financial liabilities, impacting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The Law Offices of Frank R. Cruz are urging Boston Scientific Corporation (BSX) shareholders to investigate a potential securities fraud class action.
Why It Matters
Securities fraud class actions can lead to significant financial liabilities for companies, potentially impacting Boston Scientific's stock price and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Investors in Boston Scientific (NYSE: BSX) have until May 4, 2026, to file a lead plaintiff motion in a class action for losses incurred from July 23, 2025, to February 3, 2026.
Why It Matters
The deadline for filing a lead plaintiff motion in the Boston Scientific class action could influence investor sentiment and stock price, especially for those who incurred losses during the specified period.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky, LLP is notifying investors of a pending class action against Boston Scientific (NYSE: BSX) for the period from July 23, 2025, to February 3, 2026, following a 17.6% share drop.
Why It Matters
Pending class action alerts potential legal liabilities for Boston Scientific, impacting investor confidence. The significant share price drop indicates market reaction to poor sales performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About BSX Stock
What is Boston Scientific Corporation's (BSX) stock forecast for 2026?
Based on our analysis of 33 Wall Street analysts, Boston Scientific Corporation (BSX) has a median price target of $105.00. The highest price target is $124.00 and the lowest is $83.00.
Is BSX stock a good investment in 2026?
According to current analyst ratings, BSX has 35 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $68.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BSX stock?
Wall Street analysts predict BSX stock could reach $105.00 in the next 12 months. This represents a 53.2% increase from the current price of $68.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Boston Scientific Corporation's business model?
The company operates through two main segments: MedSurg and Cardiovascular, generating revenue by providing a range of innovative medical devices for various interventional procedures. Its offerings include devices for gastrointestinal conditions, cardiac rhythm management, and neuromodulation, catering to healthcare professionals and institutions globally.
What is the highest forecasted price for BSX Boston Scientific Corporation?
The highest price target for BSX is $124.00 from Matt Miksic at Barclays, which represents a 80.9% increase from the current price of $68.55.
What is the lowest forecasted price for BSX Boston Scientific Corporation?
The lowest price target for BSX is $83.00 from at , which represents a 21.1% increase from the current price of $68.55.
What is the overall BSX consensus from analysts for Boston Scientific Corporation?
The overall analyst consensus for BSX is bullish. Out of 33 Wall Street analysts, 35 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $105.00.
How accurate are BSX stock price projections?
Stock price projections, including those for Boston Scientific Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 7:39 AM UTC